Please login to the form below

Not currently logged in

Genentech extends deal with Galapagos

Genentech has extended its drug discovery deal with Galapagos for a third time

Genentech, a member of the Roche Group, has extended its integrated contract drug discovery agreement with Galapagos' service division Argenta.

The agreement, which could be worth up to £21.5m (€23.4m), covers a number of drug discovery programmes that utilise Argenta's expertise in computer-aided drug design, medicinal chemistry, in vitro biology and screening to discover new chemical entities acting against undisclosed drug targets defined by Genentech.

The extended agreement also allows Genentech to continue placing projects directly into Galapagos' other service division, BioFocus, which will provide Genentech with integrated medicinal chemistry, in vitro biology and ADME services. 

Dr Chris Newton, senior vice-president of services of Galapagos, said: “The possibility for Genentech to continue placing projects directly with BioFocus also speaks to the complementary expertise and technological capabilities that Argenta and BioFocus possess.”

It is the third extension since the agreement was announced in December 2005.

18th August 2011


Featured jobs

Subscribe to our email news alerts


Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...